These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10942959)

  • 1. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.
    Reichert JM
    Trends Biotechnol; 2000 Sep; 18(9):364-9. PubMed ID: 10942959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopharmaceuticals: recent approvals and likely directions.
    Walsh G
    Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of and trends in the late-stage biopharmaceutical pipeline.
    Nagle PC; Nicita CA; Gerdes LA; Schmeichel CJ
    Am J Manag Care; 2008 Apr; 14(4):226-9. PubMed ID: 18402515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 8. Market watch: Upcoming market catalysts in Q3 2016.
    Ranj T
    Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354
    [No Abstract]   [Full Text] [Related]  

  • 9. Trends in US approvals: new biopharmaceuticals and vaccines.
    Reichert JM
    Trends Biotechnol; 2006 Jul; 24(7):293-8. PubMed ID: 16759723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market watch: Upcoming market catalysts in Q1 2018.
    Collins T
    Nat Rev Drug Discov; 2018 Dec; 17(1):8-9. PubMed ID: 29282372
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
    Reichert JM; Paquette C
    Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutical benchmarks--2003.
    Walsh G
    Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 15. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
    Reichert JM; Healy EM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.
    Shih HP; Zhang X; Aronov AM
    Nat Rev Drug Discov; 2018 Jan; 17(1):19-33. PubMed ID: 29075002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A look back at 2000: overabundance and deregulation.
    Prescrire Int; 2001 Apr; 10(52):52-4. PubMed ID: 11718161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.